Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Alexander Ott, Ph.D., M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA229261 (OTT, PATRICK ALEXANDER) Sep 6, 2018 - Aug 31, 2024
    Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Challenges in neoantigen-directed therapeutics. Cancer Cell. 2023 01 09; 41(1):15-40. PMID: 36368320.
    Citations: 2     Fields:    Translation:HumansCells
  2. Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022 10; 10(10). PMID: 36302562; PMCID: PMC9621185.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  3. Yeh JE, Wan MT, Alloo A, Ibrahim N, Buzurovic I, Cohen JM, Ott PA, Laga AC, Devlin PM, Lin JY. Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases. JAAD Case Rep. 2023 Jan; 31:62-65. PMID: 36505038; PMCID: PMC9731864.
  4. Long GV, Ferrucci PF, Khattak A, Meniawy TM, Ott PA, Chisamore M, Trolle T, Hyseni A, Heegaard E. KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. Future Oncol. 2022 Oct; 18(31):3473-3480. PMID: 36047545.
    Citations: 2     Fields:    Translation:Humans
  5. Lamba N, Ott PA, Iorgulescu JB. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era. JAMA Netw Open. 2022 08 01; 5(8):e2225459. PMID: 36006646; PMCID: PMC9412220.
    Citations: 3     Fields:    Translation:Humans
  6. Yeh JE, Wan MT, Alloo A, Ibrahim N, Ott PA, Buchbinder EI, Lin JY. Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma. JAAD Case Rep. 2022 Sep; 27:162-166. PMID: 36097439; PMCID: PMC9463530.
  7. Blass E, Ott PA. PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma? Clin Cancer Res. 2022 07 15; 28(14):2980-2982. PMID: 35576171; PMCID: PMC9288489.
    Citations: 1     Fields:    Translation:HumansCells
  8. Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol. 2022 07; 6:e2100413. PMID: 35797509; PMCID: PMC9848556.
    Citations:    Fields:    Translation:Humans
  9. Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D, Vonderheide RH, Domchek SM. Cancer vaccines. Cancer Cell. 2022 06 13; 40(6):559-564. PMID: 35700704; PMCID: PMC9190070.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  10. Mahmood U, Huynh MA, Killoran JH, Qian JM, Bent EH, Aizer AA, Mak RH, Mamon HJ, Balboni TA, Gunasti L, Ott PA, Awad MM, Schoenfeld JD. Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):666-675. PMID: 35643252.
    Citations: 1     Fields:    Translation:Humans
  11. Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, Zhang W, Li S, Braun DA, Neuberg D, Carr SA, Livak KJ, Frederick DT, Fritsch EF, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon CH, Keskin DB, Ott PA, Rodig SJ, Boland GM, Wu CJ. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature. 2022 05; 605(7910):532-538. PMID: 35508657; PMCID: PMC9815755.
    Citations: 14     Fields:    Translation:HumansCells
  12. Shapira-Frommer R, Mileshkin L, Manzyuk L, Penel N, Burge M, Piha-Paul SA, Girda E, Lopez Martin JA, van Dongen MGJ, Italiano A, Xu L, Jin F, Norwood K, Ott PA. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. Gynecol Oncol. 2022 08; 166(2):211-218. PMID: 35361487.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  13. Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, Guren TK, van Dongen MGJ, Spencer K, Bariani GM, Ascierto PA, Santoro A, Shah M, Asselah J, Iqbal S, Takahashi S, Piha-Paul SA, Ott PA, Chatterjee A, Jin F, Norwood K, Delord JP. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022 05; 7(5):446-454. PMID: 35114169.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  14. Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022 02; 162:22-33. PMID: 34952480.
    Citations: 5     Fields:    Translation:Humans
  15. Ott PA. Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect. Cancer Cell. 2021 11 08; 39(11):1458-1460. PMID: 34752754; PMCID: PMC9261938.
    Citations:    Fields:    Translation:AnimalsCells
  16. Ott PA, Nazzaro M, Pfaff KL, Gjini E, Felt KD, Wolff JO, Buchbinder EI, Haq R, Sullivan RJ, Lawrence DP, McDermott DF, Severgnini M, Giobbie-Hurder A, Rodig SJ, Stephen Hodi F. Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. J Immunother Cancer. 2021 11; 9(11). PMID: 34772758.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  17. Naik GS, Buchbinder EI, Cohen JV, Manos MP, Johnson AEW, Bowling P, Aizer AA, Schoenfeld JD, Lawrence DP, Haq R, Hodi FS, Sullivan RJ, Ott PA. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 10 01; 44(8):307-318. PMID: 34406158.
    Citations: 3     Fields:    Translation:Humans
  18. Klaeger S, Apffel A, Clauser KR, Sarkizova S, Oliveira G, Rachimi S, Le PM, Tarren A, Chea V, Abelin JG, Braun DA, Ott PA, Keshishian H, Hacohen N, Keskin DB, Wu CJ, Carr SA. Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Mol Cell Proteomics. 2021; 20:100133. PMID: 34391888; PMCID: PMC8724927.
    Citations: 4     Fields:    Translation:HumansCells
  19. Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick DT, Le PM, Forman J, Huang T, Li S, Zhang W, Xu Q, Cieri N, Clauser KR, Shukla SA, Neuberg D, Justesen S, MacBeath G, Carr SA, Fritsch EF, Hacohen N, Sade-Feldman M, Livak KJ, Boland GM, Ott PA, Keskin DB, Wu CJ. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021 08; 596(7870):119-125. PMID: 34290406; PMCID: PMC9187974.
    Citations: 82     Fields:    Translation:HumansCells
  20. Sanborn RE, Hamid O, de Vries EG, Ott PA, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Cho DC, Plummer R, Stroh M, Lu L, Thistlethwaite F. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. J Immunother Cancer. 2021 07; 9(7). PMID: 34301808.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  21. Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer. 2021 07; 9(7). PMID: 34301809; PMCID: PMC8311335.
    Citations: 6     Fields:    Translation:Humans
  22. Romano E, Pascolo S, Ott P. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. J Immunother Cancer. 2021 06; 9(6). PMID: 34117117.
    Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
  23. Bui AN, Tyan K, Giobbie-Hurder A, Klein IA, Manos MP, Zubiri L, Reynolds K, Grover S, Weinhouse GL, Ott PA, LeBoeuf NR, Rahma O. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. J Immunother Precis Oncol. 2021 May; 4(2):35-44. PMID: 35663537; PMCID: PMC9153254.
    Citations: 3     
  24. Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021 05; 9(5). PMID: 33963010.
    Citations: 10     Fields:    Translation:Humans
  25. Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossmann K, Guild S, Holder A, Johnson D, Joseph RW, Karakousis G, Kendra K, Lange JR, Lanning R, Margolin K, Olszanski AJ, Ott PA, Ross MI, Salama AK, Sharma R, Skitzki J, Sosman J, Wuthrick E, McMillian NR, Engh AM. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021 04 01; 19(4):364-376. PMID: 33845460.
    Citations: 42     Fields:    Translation:Humans
  26. Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C, Szabo PM, Janjigian Y, Ott PA, Sharma P, Bendell J, Evans TRJ, de Braud F, Chau I, Boyd Z. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clin Cancer Res. 2021 07 15; 27(14):3926-3935. PMID: 33782030.
    Citations: 20     Fields:    Translation:Humans
  27. Buchbinder EI, Weirather JL, Manos M, Quattrochi BJ, Sholl LM, Brennick RC, Bowling P, Bailey N, Magarace L, Ott PA, Haq R, Izar B, Giobbie-Hurder A, Hodi FS. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 04; 10(8):2627-2635. PMID: 33724703.
    Citations: 1     Fields:    Translation:Humans
  28. Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, Rahma OE. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Aug; 70(8):2209-2221. PMID: 33481042.
    Citations: 12     Fields:    Translation:Humans
  29. Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525. PMID: 33479501; PMCID: PMC8273876.
    Citations: 93     Fields:    Translation:Humans
  30. Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021 04; 18(4):215-229. PMID: 33473220; PMCID: PMC7816749.
    Citations: 157     Fields:    Translation:HumansCells
  31. Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Abdelrahim M, Khairallah P, Shirazian S, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusanio A, Blosser CD, Zuniga SC, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, Mannon RB, Shirai K, Kitchlu A, Ong S, Machado SM, Mothi SS, Ott PA, Rahma O, Hodi FS, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Riella LV, Jhaveri KD. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205. PMID: 33359528; PMCID: PMC8222056.
    Citations: 25     Fields:    Translation:Humans
  32. Poran A, Scherer J, Bushway ME, Besada R, Balogh KN, Wanamaker A, Williams RG, Prabhakara J, Ott PA, Hu-Lieskovan S, Khondker ZS, Gaynor RB, Rooney MS, Srinivasan L. Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell Rep Med. 2020 11 17; 1(8):100141. PMID: 33294862; PMCID: PMC7691446.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  33. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24. PMID: 33064988.
    Citations: 153     Fields:    Translation:HumansCellsCTClinical Trials
  34. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444. PMID: 33028595.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  35. Hirschfield GM, Beuers U, Kupcinskas L, Ott P, Bergquist A, Färkkilä M, Manns MP, Parés A, Spengler U, Stiess M, Greinwald R, Pröls M, Wendum D, Drebber U, Poupon R. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021 02; 74(2):321-329. PMID: 32950590.
    Citations: 11     Fields:    Translation:Humans
  36. Abu-Shawer O, Singh P, Yenulevich E, Brito A, Ni J, Abdulnour RE, Grover S, Manos M, Bowling P, LeBoeuf NR, Ott P, Stephen Hodi F, Jacobson J, Rahma O. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. J Immunother Cancer. 2020 08; 8(2). PMID: 32817360.
    Citations: 2     Fields:    Translation:Humans
  37. Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 08 15; 126(16):3758-3767. PMID: 32567084; PMCID: PMC7381363.
    Citations: 18     Fields:    Translation:HumansCells
  38. Grover S, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, Buchbinder EI, Ott PA, Kehl KL, Awad MM, Hodi FS, Rahma OE. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 09; 16(9):e933-e942. PMID: 32401685.
    Citations: 11     Fields:    Translation:Humans
  39. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020 07 01; 126(13):3021-3030. PMID: 32320048.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  40. Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, Rahma OE. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist. 2020 06; 25(6):505-514. PMID: 32043699; PMCID: PMC7288631.
    Citations: 36     Fields:    Translation:Humans
  41. Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, Carson Iii WE, Contreras C, Daniels GA, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossman K, Guild V, Johnson D, Karakousis G, Lange JR, Margolin K, Nath S, Olszanski AJ, Ott PA, Ross MI, Salama AK, Skitzki J, Swetter SM, Wuthrick E, McMillian NR, Engh A. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Netw. 2020 02; 18(2):120-131. PMID: 32023525.
    Citations: 9     Fields:    Translation:Humans
  42. Anandappa AJ, Wu CJ, Ott PA. Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020 02; 10(2):185-197. PMID: 31974169; PMCID: PMC7007384.
    Citations: 34     Fields:    Translation:HumansCells
  43. Truex NL, Holden RL, Wang BY, Chen PG, Hanna S, Hu Z, Shetty K, Olive O, Neuberg D, Hacohen N, Keskin DB, Ott PA, Wu CJ, Pentelute BL. Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Sci Rep. 2020 01 20; 10(1):723. PMID: 31959774.
    Citations: 8     Fields:    Translation:Humans
  44. Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T. Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer. 2020 01; 23(1):142. PMID: 31679092.
    Citations: 1     Fields:    
  45. Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol. 2020 04; 15(4):618-627. PMID: 31870883.
    Citations: 106     Fields:    Translation:Humans
  46. Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunol Res. 2020 01; 8(1):70-80. PMID: 31699709.
    Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
  47. Krimphove MJ, Tully KH, Friedlander DF, Marchese M, Ravi P, Lipsitz SR, Kilbridge KL, Kibel AS, Kluth LA, Ott PA, Choueiri TK, Trinh QD. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289. PMID: 31699149.
    Citations: 6     Fields:    Translation:Humans
  48. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2020 03; 15(3):426-435. PMID: 31629915.
    Citations: 81     Fields:    Translation:Humans
  49. Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Maglinte GA, Abraham P, Patel D, Shangguan T, Chau I. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Colorectal Cancer. 2020 03; 19(1):32-38.e3. PMID: 31813769.
    Citations: 10     Fields:    Translation:Humans
  50. Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer. 2020 01; 23(1):133-141. PMID: 31549264.
    Citations: 8     Fields:    Translation:Humans
  51. Fastow E, Cook S, Dean P, Ott P, Wilson J, Yoon H, Dietz T, Bateman F, Al-Sheikhly M. Single-Step Synthesis of Atmospheric CO2 Sorbents through Radiation-Induced Graft Polymerization on Commercial-Grade Fabrics. Radiat Res. 2019 08; 192(2):219-230. PMID: 31246533.
    Citations: 1     Fields:    Translation:Cells
  52. Ott PA, Dotti G, Yee C, Goff SL. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e70-e78. PMID: 31099621.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  53. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 04 01; 17(4):367-402. PMID: 30959471.
    Citations: 120     Fields:    Translation:Humans
  54. Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89. PMID: 30922394.
    Citations: 47     Fields:    Translation:Humans
  55. Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD. Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019; 9:199. PMID: 30984622; PMCID: PMC6450051.
    Citations: 6     
  56. Ott PA, Wu CJ. Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 2019 04; 9(4):476-481. PMID: 30862723.
    Citations: 20     Fields:    Translation:Humans
  57. Ott PA. Intralesional Cancer Immunotherapies. Hematol Oncol Clin North Am. 2019 04; 33(2):249-260. PMID: 30832998.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  58. Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019 04 01; 125(7):1113-1123. PMID: 30690710.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  59. Ott PA. Immunotherapy: An Old and New Modality for the Treatment of Cancer. Hematol Oncol Clin North Am. 2019 04; 33(2):xi-xii. PMID: 30833004.
    Citations:    Fields:    Translation:Humans
  60. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239. PMID: 30568305.
    Citations: 495     Fields:    Translation:HumansCellsCTClinical Trials
  61. Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019 02 01; 37(4):318-327. PMID: 30557521.
    Citations: 313     Fields:    Translation:HumansCellsCTClinical Trials
  62. Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol. 2019 02; 152(2):243-250. PMID: 30522700.
    Citations: 97     Fields:    Translation:HumansCTClinical Trials
  63. Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610. PMID: 30211813.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  64. Barroso-Sousa R, Ott PA. Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Curr Oncol Rep. 2018 11 15; 21(1):1. PMID: 30498900.
    Citations: 8     Fields:    Translation:Humans
  65. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018 11 12; 34(5):775-791.e3. PMID: 30423297.
    Citations: 78     Fields:    Translation:HumansAnimalsCells
  66. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. PMID: 30388455; PMCID: PMC6410377.
    Citations: 425     Fields:    Translation:HumansAnimalsCells
  67. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018 10 12; 362(6411). PMID: 30309915; PMCID: PMC6718162.
    Citations: 790     Fields:    Translation:HumansCells
  68. Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. PMID: 30227198.
    Citations: 47     Fields:    Translation:HumansCells
  69. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018 Dec; 67(12):1833-1844. PMID: 30191256; PMCID: PMC6249064.
    Citations: 26     Fields:    Translation:Humans
  70. Hu Z, Anandappa AJ, Sun J, Kim J, Leet DE, Bozym DJ, Chen C, Williams L, Shukla SA, Zhang W, Tabbaa D, Steelman S, Olive O, Livak KJ, Kishi H, Muraguchi A, Guleria I, Stevens J, Lane WJ, Burkhardt UE, Fritsch EF, Neuberg D, Ott PA, Keskin DB, Hacohen N, Wu CJ. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921. PMID: 30150207.
    Citations: 28     Fields:    Translation:HumansCells
  71. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 10 01; 36(28):2836-2844. PMID: 30110194; PMCID: PMC6161834.
    Citations: 236     Fields:    Translation:HumansCTClinical Trials
  72. Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018 08 01; 29(8):1807-1813. PMID: 29992241.
    Citations: 123     Fields:    Translation:Humans
  73. Morgan FC, Duran J, Fraile B, Karia PS, Lin JY, Ott PA, Ruiz ES, Wang DM, Zhang Y, Schmults CD. A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. J Am Acad Dermatol. 2018 Nov; 79(5):921-928. PMID: 30322559.
    Citations: 1     Fields:    Translation:Humans
  74. Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018 04 04; 6(1):26. PMID: 29618381; PMCID: PMC5885356.
    Citations: 59     Fields:    Translation:Humans
  75. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018 06 15; 24(12):2804-2811. PMID: 29559561.
    Citations: 130     Fields:    Translation:HumansCellsCTClinical Trials
  76. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402. PMID: 29542692.
    Citations: 9     Fields:    
  77. Ott PA. Immunotherapy: Immune-modified response criteria - an iterative learning process? Nat Rev Clin Oncol. 2018 05; 15(5):267-268. PMID: 29532797.
    Citations: 2     Fields:    Translation:Humans
  78. Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018 03 15; 124(6):1111-1121. PMID: 29313945.
    Citations: 34     Fields:    Translation:Humans
  79. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018 03; 18(3):168-182. PMID: 29226910; PMCID: PMC6508552.
    Citations: 309     Fields:    Translation:HumansCellsPHPublic Health
  80. Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget. 2017 Dec 05; 8(63):106169-106170. PMID: 29290936.
    Citations: 10     Fields:    
  81. Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215. PMID: 29101162; PMCID: PMC5809290.
    Citations: 186     Fields:    Translation:HumansAnimalsCells
  82. Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20; 35(36):4035-4041. PMID: 29095678.
    Citations: 167     Fields:    Translation:HumansCTClinical Trials
  83. Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Res. 2017 12; 5(12):1133-1140. PMID: 29079654.
    Citations: 51     Fields:    Translation:HumansCells
  84. Ott PA, Soria JC. Reply to F. Tomao et al. J Clin Oncol. 2017 11 01; 35(31):3633-3634. PMID: 28880745.
    Citations:    Fields:    Translation:Humans
  85. Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 01; 35(34):3823-3829. PMID: 28813164.
    Citations: 185     Fields:    Translation:HumansCTClinical Trials
  86. Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017; 5:66. PMID: 28815046.
  87. Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017 08 15; 5(1):66. PMID: 28807048.
    Citations: 12     Fields:    Translation:Humans
  88. Moreira RB, Hamieh L, Gjini E, Lako A, Krajewski KM, Yoon CH, Ott PA. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. J Immunother Cancer. 2017 07 18; 5(1):61. PMID: 28716097.
    Citations:    Fields:    Translation:Humans
  89. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221. PMID: 28678778; PMCID: PMC5577644.
    Citations: 1052     Fields:    Translation:HumansCellsCTClinical Trials
  90. Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. PMID: 28662869.
    Citations: 27     Fields:    Translation:Humans
  91. Goldman C, Tchack J, Robinson EM, Han SW, Moran U, Polsky D, Berman RS, Shapiro RL, Ott PA, Osman I, Zhong H, Pavlick AC, Wilson MA. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology. 2017; 93(3):164-176. PMID: 28601879.
    Citations: 1     Fields:    Translation:Humans
  92. Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. PMID: 28592629; PMCID: PMC5559305.
    Citations: 46     Fields:    Translation:Humans
  93. Ott P, Calvo E, Sharma P, Jaeger D, Ascierto P, Chau I, Bendell J, Peltola K, Taylor M, Tschaika M, Dorange C, Janjigian Y, Le D. Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. Ann Oncol. 2017 Jun; 28 Suppl 3:iii139. PMID: 32135767.
  94. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541. PMID: 28489510.
    Citations: 152     Fields:    Translation:HumansCTClinical Trials
  95. Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA. Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2017 05; 133(1):221. PMID: 28527005.
    Citations:    Fields:    
  96. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 05 01; 28(5):1036-1041. PMID: 28453692; PMCID: PMC5406758.
    Citations: 89     Fields:    Translation:HumansCTClinical Trials
  97. Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05; 5(5):357-362. PMID: 28396509; PMCID: PMC5502536.
    Citations: 21     Fields:    Translation:Humans
  98. Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, Weinberg J, Donahue H, Bailey N, Hodi FS, Buchbinder EL, Ott PA. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunol Res. 2017 04; 5(4):286-291. PMID: 28373217.
    Citations: 16     Fields:    Translation:Humans
  99. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer Metastasis Rev. 2017 03; 36(1):43-50. PMID: 28181070.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  100. Hermel DJ, Ott PA. Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer Metastasis Rev. 2017 03; 36(1):51. PMID: 28326450.
    Citations: 1     Fields:    
  101. De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318. PMID: 28246107; PMCID: PMC5418853.
    Citations: 177     Fields:    
  102. George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204. PMID: 28228279; PMCID: PMC5408320.
    Citations: 224     Fields:    Translation:HumansCellsCTClinical Trials
  103. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. PMID: 28239469; PMCID: PMC5319100.
    Citations: 169     Fields:    Translation:HumansAnimals
  104. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351. PMID: 28463153.
    Citations: 66     Fields:    Translation:Humans
  105. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EM, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 Feb 07. PMID: 28168292.
  106. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017 Jun 15; 23(12):3214-3222. PMID: 27852700; PMCID: PMC5433927.
    Citations: 21     Fields:    Translation:Humans
  107. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. PMID: 27528724; PMCID: PMC5657013.
    Citations: 81     Fields:    Translation:HumansCTClinical Trials
  108. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016 Nov; 17(11):1590-1598. PMID: 27733243; PMCID: PMC5648054.
    Citations: 283     Fields:    Translation:HumansCTClinical Trials
  109. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov; 17(11):1558-1568. PMID: 27622997; PMCID: PMC5630525.
    Citations: 372     Fields:    Translation:HumansCTClinical Trials
  110. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060. PMID: 27535979; PMCID: PMC5161686.
    Citations: 161     Fields:    Translation:HumansCTClinical Trials
  111. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362. PMID: 27533633; PMCID: PMC5134420.
    Citations: 110     Fields:    Translation:Humans
  112. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353. PMID: 27533448; PMCID: PMC5767160.
    Citations: 139     Fields:    Translation:Humans
  113. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. PMID: 27532025; PMCID: PMC4986340.
    Citations: 196     Fields:    
  114. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58. PMID: 27496110.
    Citations: 32     Fields:    Translation:Humans
  115. Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2016 09; 129(3):389-393. PMID: 27401151.
    Citations: 4     Fields:    Translation:Humans
  116. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 09; 90(3):638-47. PMID: 27282937; PMCID: PMC4983464.
    Citations: 215     Fields:    Translation:Humans
  117. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul; 17(7):883-895. PMID: 27269741.
    Citations: 524     Fields:    Translation:HumansCTClinical Trials
  118. Ott PA, Hodi FS. Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016 07 01; 22(13):3127-31. PMID: 27146699.
    Citations: 35     Fields:    Translation:HumansCells
  119. Marmarelis ME, Davis MR, Sethi NS, Krajewksi KM, McKay RR, Choueiri TK, Ott PA. Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. J Immunother Cancer. 2016; 4:26. PMID: 27099755.
    Citations:    Fields:    
  120. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. PMID: 26633184.
    Citations: 244     Fields:    Translation:Humans
  121. Ott PA. Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. Ann Transl Med. 2015 Nov; 3(20):313. PMID: 26697473; PMCID: PMC4669316.
    Citations: 2     
  122. Ott PA, Hodi FS, Buchbinder EI. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5:202. PMID: 26442214; PMCID: PMC4585112.
    Citations: 103     
  123. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Oct; 3(10):1185-92. PMID: 26100356.
    Citations: 93     Fields:    Translation:Humans
  124. Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, Chin G, Luke JJ, Ott PA, Hodi FS, Mihm MC, Lin JY, Werchniak AE, Haynes HA, Bailey N, Liu R, Murphy GF, Lian CG. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics. 2015; 7:59. PMID: 26221190.
    Citations: 30     Fields:    
  125. Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 Nov; 4(11):e1046028. PMID: 26451318.
    Citations: 93     Fields:    
  126. Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015 Sep; 3(9):986-91. PMID: 25943535; PMCID: PMC4561189.
    Citations: 14     Fields:    Translation:Humans
  127. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21; 372(21):2006-17. PMID: 25891304; PMCID: PMC5744258.
    Citations: 1170     Fields:    Translation:Humans
  128. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015 Feb 28; 6(6):3479-92. PMID: 25682878; PMCID: PMC4414130.
    Citations: 73     Fields:    Translation:Humans
  129. Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res. 2015 Mar; 3(3):278-287. PMID: 25633712; PMCID: PMC4374362.
    Citations: 38     Fields:    Translation:HumansCellsPHPublic Health
  130. Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015 Feb 15; 21(4):749-55. PMID: 25538262; PMCID: PMC4334697.
    Citations: 88     Fields:    Translation:Humans
  131. Luke JJ, Ott PA, Shapiro GI. The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28. PMID: 25414119.
    Citations: 15     Fields:    Translation:HumansCells
  132. Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014 Nov 10; 32(32):3659-66. PMID: 25267741.
    Citations: 43     Fields:    Translation:HumansCTClinical Trials
  133. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf. 2014; 6:77-88. PMID: 25018652.
    Citations: 13     
  134. Ott PA, Fritsch EF, Wu CJ, Dranoff G. Vaccines and melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):559-69. PMID: 24880947.
    Citations: 9     Fields:    Translation:HumansCells
  135. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun; 2(6):522-9. PMID: 24894089.
    Citations: 103     Fields:    Translation:HumansCells
  136. Ott PA, Bhardwaj N. Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol. 2013 Oct 28; 4:346. PMID: 24194739.
    Citations: 18     Fields:    
  137. Luke JJ, Ott PA. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? Expert Opin Pharmacother. 2013 Dec; 14(18):2457-62. PMID: 24138302.
    Citations: 8     Fields:    Translation:HumansAnimals
  138. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013 Oct 01; 19(19):5300-9. PMID: 24089443.
    Citations: 289     Fields:    Translation:Humans
  139. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95. PMID: 23913718; PMCID: PMC3986037.
    Citations: 83     Fields:    Translation:Humans
  140. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, Golfinos JG, Parker EC, Huang PP, Narayana A. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013 Jun; 23(3):191-5. PMID: 23462208.
    Citations: 83     Fields:    Translation:Humans
  141. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32. PMID: 23716015.
    Citations: 52     Fields:    Translation:Humans
  142. Ott PA, Hodi FS. Treatment for advanced melanoma: new drugs, new opportunities, new challenges. Oncology (Williston Park). 2013 May; 27(5):381-92, 391. PMID: 25184259.
    Citations: 1     Fields:    Translation:Humans
  143. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol. 2013 Jul; 113(3):411-6. PMID: 23579338.
    Citations: 48     Fields:    Translation:Humans
  144. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. PMID: 23569304.
    Citations: 171     Fields:    Translation:HumansCellsCTClinical Trials
  145. Ott PA, Hodi FS. The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chin Clin Oncol. 2013 Mar; 2(1):7. PMID: 25841448.
    Citations: 5     Fields:    
  146. Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, Bhardwaj N. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother. 2013 Apr; 62(4):811-22. PMID: 23306863.
    Citations: 60     Fields:    Translation:HumansCells
  147. Ott PA, Provalov AV, Vazhenin AV, Nadvikova EA, Kandakova EIu, Zabolotskaia EG. [Long-term results of combined treatment of soft tissue sarcoma with the use of intraoperative radiotherapy]. Klin Med (Mosk). 2013; 91(3):65-7. PMID: 23789456.
    Citations:    Fields:    Translation:Humans
  148. Ott PA, Privalov AV, Vazhenin AV, Chekha NA, Zabolotskaia EG, Komissarov AV. [Results of combined treatment with intraoperative radial therapy of soft tissue sarcoma]. Vestn Khir Im I I Grek. 2013; 172(1):99-101. PMID: 23808238.
    Citations:    Fields:    Translation:Humans
  149. Ott PA, Privalov AV, Vazhenin AV, Nadvikova EA, Lukina EIu, Komissarov AV, Zabolotskaia EG. [Immediate results of combined treatment for soft tissue sarcomas including intraoperative radiation therapy]. Vopr Onkol. 2013; 59(5):603-5. PMID: 24260888.
    Citations:    Fields:    Translation:Humans
  150. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9. PMID: 23248257.
    Citations: 199     Fields:    Translation:HumansCTClinical Trials
  151. Ott PA, Chang J, Madden K, Kannan R, Muren C, Escano C, Cheng X, Shao Y, Mendoza S, Gandhi A, Liebes L, Pavlick AC. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol. 2013 Jan; 71(1):183-91. PMID: 23064957.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  152. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs. 2013 Apr; 31(2):425-34. PMID: 22864522.
    Citations: 66     Fields:    Translation:HumansCTClinical Trials
  153. Ma MW, Medicherla RC, Qian M, Vega-Saenz de Miera E, Friedman EB, Berman RS, Shapiro RL, Pavlick AC, Ott PA, Bhardwaj N, Shao Y, Osman I, Darvishian F. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol. 2012 Jul; 25(7):1000-10. PMID: 22425909; PMCID: PMC3882943.
    Citations: 21     Fields:    Translation:Humans
  154. Seetharamu N, Tu TJ, Christos P, Ott PA, Berman RS, Shapiro RL, Osman I, Pavlick AC. Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Oncology. 2011; 81(5-6):403-9. PMID: 22270052.
    Citations: 2     Fields:    Translation:Humans
  155. Chang JL, Ott PA, Sorlie C, Escano C, Yepes E, Mendoza S, Gandhi A, Liebes L, Pavlick AC. Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). J Clin Oncol. 2011 May 20; 29(15_suppl):8545. PMID: 28021078.
  156. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy. 2011 Feb; 3(2):213-27. PMID: 21322760.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  157. Ott PA, Berman RS. Surgical approach to primary cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan; 20(1):39-56. PMID: 21111958.
    Citations: 2     Fields:    Translation:Humans
  158. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One. 2010 Dec 29; 5(12):e15588. PMID: 21206909.
    Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
  159. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a case-based review of the literature. Oncologist. 2010; 15(7):772-81. PMID: 20571149.
    Citations: 32     Fields:    Translation:Humans
  160. Ott PA, Hamilton A, Jones A, Haas N, Shore T, Liddell S, Christos PJ, Doyle LA, Millward M, Muggia FM, Pavlick AC. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One. 2010 Jan 20; 5(1):e8714. PMID: 20098694.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  161. Seetharamu N, Ott PA, Pavlick AC. Novel therapeutics for melanoma. Expert Rev Anticancer Ther. 2009 Jun; 9(6):839-49. PMID: 19496721.
    Citations: 9     Fields:    Translation:HumansAnimals
  162. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman E, Venhaus R, Pan L, Old L, Pavlick AC, Wolchok JD. Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). J Clin Oncol. 2009 May 20; 27(15_suppl):9030. PMID: 27962087.
  163. Pavlick AC, Ott P, Escalon J, Madden K, Yepes E, Staha J, Mendoza S, Gandhi A, Yee H, Liebes L. Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. J Clin Oncol. 2009 May 20; 27(15_suppl):9080. PMID: 27962199.
  164. Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy. 2009; 55(4):221-7. PMID: 19451711.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  165. Ott P, Benke I, Stelzer J, Köhler C, Hanefeld M. ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. Dtsch Med Wochenschr. 2009 Feb; 134(7):291-7. PMID: 19197810.
    Citations: 11     Fields:    Translation:Humans
  166. Ott PA, Pavlick AC, Zoloretev A, Ng B, Buckley MT, Brooks PP, Liebes L. Correlation of shedding cryptic epitope (HU177) levels and treatment response in sera of melanoma patients. J Clin Oncol. 2008 May 20; 26(15_suppl):20018. PMID: 27947817.
  167. Koehler C, Ott P, Benke I, Hanefeld M. Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. Horm Metab Res. 2007 Sep; 39(9):632-5. PMID: 17846969.
    Citations: 18     Fields:    Translation:Humans
  168. Ott PA, Tary-Lehmann M, Lehmann PV. The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types. Clin Immunol. 2007 Sep; 124(3):267-76. PMID: 17632036; PMCID: PMC2083259.
    Citations: 5     Fields:    Translation:AnimalsCells
  169. Quast S, Zhang W, Shive C, Kovalovski D, Ott PA, Herzog BA, Boehm BO, Tary-Lehmann M, Karulin AY, Lehmann PV. IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell Immunol. 2005 Sep; 237(1):28-36. PMID: 16256965.
    Citations: 17     Fields:    Translation:HumansCells
  170. Hofstetter HH, Karulin AY, Forsthuber TG, Ott PA, Tary-Lehmann M, Lehmann PV. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J Neuroimmunol. 2005 Dec 30; 170(1-2):105-14. PMID: 16257061.
    Citations: 18     Fields:    Translation:AnimalsCells